Business
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
FIRST PATIENT ACHIEVED STABLE DISEASE WITH NO ADVERSE SIDE EFFECTSLOS ANGELES, CA / ACCESSWIRE / May 27, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"FIRST PATIENT ACHIEVED STABLE DISEASE WITH NO ADVERSE SIDE EFFECTSLOS ANGELES, CA / ACCESSWIRE / May 27, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on NK cell engager (TriKE™) technology. GT announced today that the second patient of the lowest dose of an ascending dose finding study has begun treatment of the GTB-3550 TriKE™. The patient will be evaluated following completion of the third cycle of GTB-3550 TriKE™ therapy. The clinical trial is being conducted at the University of Minnesota's Masonic Cancer Center in Minneapolis. Additional clinical trial sites are now being processed.The first patient of the Phase I/II study achieved stable disease and increased NK cell production with no adverse side effects. The first patient elicited an encouraging initial efficacy marker response.The TRIKE™ clinical trial evaluates GTB-3550 in patients with acute myeloid leukemia or advanced systemic mastocytosis, and will determine safety and tolerability as well as the pharmacologically active dose and maximum tolerated dose of GTB-3550.TriKE™ is a multi-targeted immuno-oncology protein-based therapeutic drug. The TriKE™ addresses the patient delivery and administration issues of liquid tumor cell therapies and NK engagers. Pre-clinical data shows that The TriKE™ platform technology works in both liquid and solid tumors.About GTB-3550 Trispecific NK cell Engager (TriKE™)GTB-3550 is the Company's first TriKE™ product candidate being initially developed for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The natural killer (NK) cell stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates NK cells and enhances their ability to kill. The Company is currently in a clinical trial with GTB-3550 in CD33 positive leukemia for acute myeloid leukemia (AML), and is studying myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies along with other solid tumor candidates.About GT Biopharma, Inc.GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our propriet...